BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 30826425)

  • 1. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
    Shahid M; Kim J; Leaver K; Hendershott T; Zhu D; Cholerton B; Henderson VW; Tian L; Poston KL
    Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
    J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E ε4 genotype and risk of freezing of gait in Parkinson's disease.
    Kim R; Shin JH; Park S; Kim HJ; Jeon B
    Parkinsonism Relat Disord; 2020 Dec; 81():173-178. PubMed ID: 33161290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
    Tropea TF; Xie SX; Rick J; Chahine LM; Dahodwala N; Doshi J; Davatzikos C; Shaw LM; Van Deerlin V; Trojanowski JQ; Weintraub D; Chen-Plotkin AS
    Mov Disord; 2018 Feb; 33(2):289-297. PubMed ID: 29168904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Apolipoprotein E ε4 in Early and Late Mild Cognitive Impairment.
    Luo Y; Tan L; Therriault J; Zhang H; Gao Y;
    Eur Neurol; 2021; 84(6):472-480. PubMed ID: 34340229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.
    Mormino EC; Betensky RA; Hedden T; Schultz AP; Ward A; Huijbers W; Rentz DM; Johnson KA; Sperling RA; ; ;
    Neurology; 2014 May; 82(20):1760-7. PubMed ID: 24748674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.
    Bekris LM; Tsuang DW; Peskind ER; Yu CE; Montine TJ; Zhang J; Zabetian CP; Leverenz JB
    Mov Disord; 2015 Jun; 30(7):936-44. PubMed ID: 25808939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and neurochemical correlates of the APOE genotype in early-stage Parkinson's disease.
    Zenuni H; Bovenzi R; Bissacco J; Grillo P; Simonetta C; Mascioli D; Pieri M; Bernardini S; Sancesario GM; Stefani A; Mercuri NB; Schirinzi T
    Neurobiol Aging; 2023 Nov; 131():24-28. PubMed ID: 37572524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex differences in CSF biomarkers vary by Alzheimer disease stage and
    Babapour Mofrad R; Tijms BM; Scheltens P; Barkhof F; van der Flier WM; Sikkes SAM; Teunissen CE
    Neurology; 2020 Oct; 95(17):e2378-e2388. PubMed ID: 32788242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Physical Activity and
    Kim R; Park S; Yoo D; Jun JS; Jeon B
    Neurology; 2021 May; 96(19):e2429-e2437. PubMed ID: 33790041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
    Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
    Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.
    Lim YY; Kalinowski P; Pietrzak RH; Laws SM; Burnham SC; Ames D; Villemagne VL; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe CC; Masters CL; Maruff PT
    JAMA Neurol; 2018 Apr; 75(4):488-494. PubMed ID: 29356823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment.
    Insel PS; Hansson O; Mattsson-Carlgren N
    JAMA Neurol; 2021 Feb; 78(2):229-235. PubMed ID: 33044487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of APOE-ε4 and GAP-43-related presynaptic loss with β-amyloid, tau, neurodegeneration, and cognitive decline.
    Lan G; Du J; Chen X; Wang Q; ; Han Y; Guo T
    Neurobiol Aging; 2023 Dec; 132():209-219. PubMed ID: 37852045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.
    Siderowf A; Xie SX; Hurtig H; Weintraub D; Duda J; Chen-Plotkin A; Shaw LM; Van Deerlin V; Trojanowski JQ; Clark C
    Neurology; 2010 Sep; 75(12):1055-61. PubMed ID: 20720189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-Related Association Between APOE ɛ4 and Cognitive Progression in de novo Parkinson's Disease.
    Liu JY; Ma LZ; Wang J; Cui XJ; Sheng ZH; Fu Y; Li M; Ou YN; Yu JT; Tan L; Lian Y
    J Alzheimers Dis; 2023; 91(3):1121-1132. PubMed ID: 36565124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.